The human immune system consists on two distinct types of immunity: humoral immunity and cell mediated (CMI). CMI measurement is usefull in a variety of applications, including transplantation, autoimmunity, cancer...
Potent immunosuppressive drugs have reduced the incidence of allograft rejection while increasing susceptibility to infection and malignancy.
Over-immunosuppressed patients are at increased risk for opportunistic infections, including reactivation of latent viral infections. It is recommended that transplant patients be monitored closely for signs of over-immunosuppression to reduce the risk of infection.
Immunosuppressant drug monitoring is insufficient for determining the level of immunosuppression or directing changes in treatment regimens.
Cylex patented technology combines cell stimulation, cell selection and quantification of metabolic markers (eg., ATP) to measure the overall cell-mediated immune response of CD4.
ImmuKnow is a noninvasive means of rapidly providing a biomarker of immunosuppressed population cellular immune status.
This test provides a measure of immune function, not just CD4 counts which do not always reflect the actual status of the patient’s immune system. ImmuKnow measures early response to stimulation by detecting the intracellular synthesis of ATP in CD4 cells.
This measurement is performed on whole blood anticoagulated with heparin using a luminometer and luciferin / luciferase.